Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Urinary Bladder Neck Obstruction 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, B-Cell 1Lung Neoplasms 1Lower Urinary Tract Symptoms 1Erectile Dysfunction 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

fludarabine phosphate 16Cyclophosphamide 15Peripheral Blood Stem Cell Transplantation 10Tacrolimus 9Busulfan 9Whole-Body Irradiation 8Mycophenolic Acid 8fludarabine 6Methotrexate 6Cyclosporine 6Radiotherapy 5ruxolitinib 4Biopsy 4Antilymphocyte Serum 4Specimen Handling 3Decitabine 3peginterferon alfa-2a 2givinostat hydrochloride 2givinostat 2bomedemstat 2Stem Cell Transplantation 2Prednisone 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methylprednisolone 2Melphalan 2Imatinib Mesylate 2Filgrastim 2Etoposide 2Cytarabine 2Aspirin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thrombocythemia, Essential × mirabegron × Clear all
NCT02311569 2019-05-15

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Swiss Cancer Institute

Phase 2 Completed
39 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡